Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, January 2nd.
According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “
A number of other equities research analysts have also recently commented on AUPH. Vetr cut Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating and set a $6.64 price objective for the company. in a research note on Wednesday, September 6th. Canaccord Genuity set a $11.00 target price on Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, October 24th. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 15th. ValuEngine upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Seaport Global Securities restated a “buy” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, October 6th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $10.79.
Shares of Aurinia Pharmaceuticals (NASDAQ AUPH) traded down $0.07 during trading on Tuesday, reaching $5.62. The company’s stock had a trading volume of 749,769 shares, compared to its average volume of 1,190,000. Aurinia Pharmaceuticals has a 12-month low of $2.95 and a 12-month high of $10.54. The firm has a market capitalization of $471.93, a PE ratio of -4.64 and a beta of 2.34.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 18,089.02% and a negative return on equity of 25.56%. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.03 million. Aurinia Pharmaceuticals’s revenue was up .0% compared to the same quarter last year. equities analysts expect that Aurinia Pharmaceuticals will post -1.08 earnings per share for the current year.
Several hedge funds have recently bought and sold shares of the company. Alyeska Investment Group L.P. lifted its holdings in shares of Aurinia Pharmaceuticals by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 681,517 shares of the biotechnology company’s stock valued at $4,273,000 after purchasing an additional 12,171 shares in the last quarter. Cutler Capital Management LLC lifted its holdings in Aurinia Pharmaceuticals by 33.3% during the third quarter. Cutler Capital Management LLC now owns 40,000 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 10,000 shares during the period. Investment Centers of America Inc. lifted its holdings in Aurinia Pharmaceuticals by 100.0% during the third quarter. Investment Centers of America Inc. now owns 60,000 shares of the biotechnology company’s stock worth $376,000 after acquiring an additional 30,000 shares during the period. Wells Fargo & Company MN lifted its holdings in Aurinia Pharmaceuticals by 13,197.5% during the third quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 26,395 shares during the period. Finally, Ameriprise Financial Inc. lifted its holdings in Aurinia Pharmaceuticals by 39.7% during the third quarter. Ameriprise Financial Inc. now owns 211,569 shares of the biotechnology company’s stock worth $1,327,000 after acquiring an additional 60,101 shares during the period. Institutional investors own 28.09% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Lowers Aurinia Pharmaceuticals (NASDAQ:AUPH) to Sell” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/28/aurinia-pharmaceuticals-auph-lowered-to-sell-at-zacks-investment-research.html.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.